BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 25757876)

  • 1. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
    Liu S; Wang H; Zhang L; Tang C; Jones L; Ye H; Ban L; Wang A; Liu Z; Lou F; Zhang D; Sun H; Dong H; Zhang G; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Huang XF; Chen SY; Zhou T
    Hum Genomics; 2015 Feb; 9(1):2. PubMed ID: 25757876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
    Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
    Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Mutation Detection for Risk Assessment in Patients with Breast Cancer by Using Next-Generation Sequencing.
    Liu PF; Zhuo ZL; Xie F; Xian HP; Liu C; Wang S; Zhao XT
    Ann Clin Lab Sci; 2021 Sep; 51(5):670-677. PubMed ID: 34686509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform.
    Fan C; Liu N; Fan S; Yang Z; Ye N; Wang K
    Oncol Rep; 2019 Oct; 42(4):1580-1588. PubMed ID: 31364747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
    Bai X; Zhang E; Ye H; Nandakumar V; Wang Z; Chen L; Tang C; Li J; Li H; Zhang W; Han W; Lou F; Zhang D; Sun H; Dong H; Zhang G; Liu Z; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Jones L; Huang XF; Chen SY; Gao J
    PLoS One; 2014; 9(6):e99306. PubMed ID: 24918944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance characteristics of the AmpliSeq Cancer Hotspot panel v2 in combination with the Ion Torrent Next Generation Sequencing Personal Genome Machine.
    Butler KS; Young MY; Li Z; Elespuru RK; Wood SC
    Regul Toxicol Pharmacol; 2016 Feb; 74():178-86. PubMed ID: 26387931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
    Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
    PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.
    Yamaguchi T; Mukai H; Yamashita S; Fujii S; Ushijima T
    Oncology; 2015; 88(6):377-84. PubMed ID: 25591616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
    Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
    Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncovering the genomic heterogeneity of multifocal breast cancer.
    Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
    J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel
    Bae GE; Yoon N; Cho EY; Kim HS; Cho SY
    Anticancer Res; 2019 Jan; 39(1):369-374. PubMed ID: 30591482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
    BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exploratory study of circulating tumor DNA detection in early breast cancer: an analysis of 75 next-generation sequencing results].
    Zhou B; Xin L; Xu L; Liu YH; Zhang MM; Jing RL; Liang XY; Cao SB
    Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):847-852. PubMed ID: 29136733
    [No Abstract]   [Full Text] [Related]  

  • 19. Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer.
    Ross JS; Gay LM
    Pathology; 2017 Feb; 49(2):120-132. PubMed ID: 28034454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
    Zheng H; Wang Y; Tang C; Jones L; Ye H; Zhang G; Cao W; Li J; Liu L; Liu Z; Zhang C; Lou F; Liu Z; Li Y; Shi Z; Zhang J; Zhang D; Sun H; Dong H; Dong Z; Guo B; Yan HE; Lu Q; Huang X; Chen SY
    Cancer Genomics Proteomics; 2016; 13(3):231-8. PubMed ID: 27107065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.